We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+19.58%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$161M
AUM Growth
+$20.9M
Cap. Flow
-$8.51M
Cap. Flow %
-5.29%
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$4.07M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.08M
3
CBAY
Cymabay Therapeutics
CBAY
+$2.81M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$2.01M
5
TVRD
Tvardi Therapeutics
TVRD
+$1.31M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.22M
2
SPNC
Spectranetics Corp
SPNC
+$2.15M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.98M
4
CLLS
Cellectis
CLLS
+$1.97M
5
IMMU
Immunomedics Inc
IMMU
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 90.71%
2 Miscellaneous 9.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$24.1M 14.99%
262,121
-41,500
-14% -$3.22M
ATRC icon
2
AtriCure
ATRC
$2.47B
$8.59M 5.34%
384,145
– –
ONC
3
BeOne Medicines Ltd
ONC
$41.5B
$7.43M 4.62%
71,849
-1,187
-2% -$88.5K
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$6.44M 4%
460,451
-177,249
-28% -$1.77M
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.51B
$6.25M 3.88%
1,193,228
+602,100
+102% +$3.08M
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
$5.96M 3.7%
216,119
– –
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$5.67M 3.52%
116,770
+10,000
+9% +$546K
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$5.29M 3.29%
76,000
-6,000
-7% -$321K
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$4.24M 2.63%
346,013
+125,000
+57% +$1.3M
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$3.51M 2.18%
435,000
+415,933
+2,181% +$2.81M
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.7B
$3.34M 2.07%
54,508
– –
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
$3.23M 2%
718,272
+451,772
+170% +$2.01M
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.22M 2%
31,609
-7,000
-18% -$612K
PODD icon
14
Insulet
PODD
$10.1B
$3.17M 1.97%
57,484
-6,000
-9% -$328K
IBB icon
15
iShares Biotechnology ETF
IBB
$10.5B
$2.9M 1.8%
26,100
– –
MGNX icon
16
MacroGenics
MGNX
$263M
$2.85M 1.77%
154,200
+35,000
+29% +$606K
DXCM icon
17
DexCom
DXCM
$34.3B
$2.81M 1.75%
+230,000
New +$4.07M
AKBA icon
18
Akebia Therapeutics
AKBA
$243M
$2.67M 1.66%
135,738
– –
ASND icon
19
Ascendis Pharma A/S
ASND
$16.3B
$2.62M 1.63%
72,226
+39,012
+117% +$1.12M
VYGR icon
20
Voyager Therapeutics
VYGR
$218M
$2.41M 1.5%
117,259
-87,549
-43% -$988K
RDUS
21
DELISTED
Radius Health, Inc.
RDUS
$2.06M 1.28%
53,309
– –
DERM
22
DELISTED
Dermira, Inc.
DERM
$2.04M 1.27%
75,500
– –
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
$1.84M 1.14%
52,500
-3,309
-6% -$44.9K
ARDX icon
24
Ardelyx
ARDX
$984M
$1.82M 1.13%
325,409
-48,000
-13% -$253K
SYRE icon
25
Spyre Therapeutics
SYRE
$7.97B
$1.72M 1.07%
13,984
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, DAFNA Capital Management held 88 positions worth $161M, up 15% from $140M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $8.51M in Q3 2017, closing 14 positions and reducing 19 holdings. Its most notable exit was Spectranetics Corp, an estimated $2.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in DexCom worth $2.81M.

  • DAFNA Capital Management's largest Q3 2017 buy was DexCom: 230,000 shares worth $2.81M.
  • DAFNA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $3.08M increase.
  • DAFNA Capital Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $3.22M.
  • DAFNA Capital Management fully exited Spectranetics Corp in Q3 2017, selling an estimated $2.15M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $161M portfolio in Q3 2017.
  • DAFNA Capital Management opened 12 new positions and closed 14 in Q3 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $161M.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.